SPECTRUM 2026, January 15-17

Leeds and Montpellier, December 4, 2025 – Leeds Teaching Hospitals has acquired Quantum Surgical’s Epione® robotic platform and has become the fastest-growing center in terms of procedures, having already treated more than 25 patients in less than 10 weeks. This innovative technology is used to treat early-stage cancerous tumours.

Quantum Surgical, a company specializing in robotics and AI, develops the Epione® robotic platform. It assists physicians in performing percutaneous tumour ablations, where one or more needles are inserted through the skin to destroy the tumour. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

Leeds Teaching Hospitals patients have benefited from these percutaneous ablation techniques for over 20 years.

Thanks to Epione, Leeds Teaching Hospitals can now offer patients with liver and kidney cancer this robotic-assisted technology. Patients treated with this new robotics technology can benefit from less post-operative pain, shorter stays in hospital and potentially curative outcomes, recovering at home in a few days.

Paul Woodwards, 67 from Leeds, recently underwent the procedure to treat liver cancer. The tumour in his liver was broken down using the robot-guided procedure and he was able to be home within four days with minimal discomfort. He will now be monitored for up to 10 years to see if the cancer has been successfully treated.

“I feel very lucky to have been offered this procedure. It was brilliant to be at the forefront of such cutting-edge treatment. I was happy to be able to come home and recover within such a short space of time without needing to have a long hospital stay.”

“The staff have been absolutely wonderful, every member of the team has looked after me, checking up on me and reassuring me through my recovery afterwards. I am hopeful that other patients and families facing a cancer diagnosis will be able to benefit from this technology and to have more accurate treatments in the future.”

Dr. James Lenton and his team are convinced of the added value Epione brings, having already treated more than 25 patients. This makes Leeds the hospital with the fastest rollout in performing procedures.

Dr. James Lenton, Consultant Interventional Radiologist at Leeds Teaching Hospitals, explains: “Utilising the Epione system is helping us to deliver care and perform less invasive more precise treatment. This reduces disruption to patients’ wellbeing and gives shorter hospital stays allowing us to manage more cases. We are pleased to have integrated the robot into our practice and to have already treated so many patients with it.”

Dr Magnus Harrison, Chief Medical Officer at Leeds Teaching Hospitals says: “At Leeds Teaching Hospitals, our aim is to offer patients the most advanced and innovative treatments while improving their comfort and overall experience. Acquiring the Epione system is a strategic step in that mission, and we are proud to offer this new therapeutic option to our patients”.

“We are very proud of how quickly the Epione robotic system has been adopted at Leeds Teaching Hospitals. Dr. Lenton and his team’s rapid uptake of the platform clearly demonstrates its added value: it streamlines workflow, enhances precision, and enables the treatment of a greater number of patients. Their leadership sets an example for physicians across the UK” declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione® device is CE marked for abdomen, chest and musculoskeletal structures indications, and FDA cleared for abdominal ablation indication. Over 1,200 patients have already been treated in Europe and the United States.

Since 1988, the annual scientific meeting of the British Society of Interventional Radiology has provided a platform for knowledge exchange and networking for interventionalists throughout Britain and beyond.

The BSIR 2025 annual scientific meeting will take place from 11^th-13^th November, 2025, in Liverpool, UK.

‍

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione^® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

‍

Event Details:

• Date: November 11-13th, 2025
• Location: ACC Liverpool, UK
• BSIR Annual Meeting website

‍

Montpellier, September 4^th 2025– Quantum Surgical has obtained CE mark approval for the expanded use of its Epione® robotic platform in the treatment of bone tumors and metastases. The platform can also be used for bone consolidation. A third of cancer patients suffer from bone metastasis[1]. This new indication will be presented during the CIRSE congress, the largest interventional radiology event worldwide, held in Barcelona from September 13^th to15^th.

Quantum Surgical, acompany specializing in robotics and AI, develops the Epione^® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

 Epione allows physiciansto treat inoperable tumors that are particularly difficult to reach, due totheir size or their location, at an early stage, in a simple and effective way. 

 Epione® could until now be used to treat tumors in the abdomen (including the liver, kidneys, and pancreas) and the in the chest (lung). Over 1,000 patients have already been treated in Europe and the United States.  

Based on a clinical study conducted in three French hospitals - Gustave Roussy (Villejuif, the leading cancer center in Europe (4^th worldwide[2]), the Paoli-Calmettes Institute (Marseille) and the Hospices Civils de Lyon - the CE mark approval for bone tumors will expand this innovative, targeted, and minimally invasive treatment to new patients in Europe.

 Thanks to the new indication, Epione can also be used for other percutaneous procedures, such as bone consolidation (pelvis and spine). Bone consolidation can help reduce patients’ pain and improve their mobility[3].  

 “Given that a third of cancer patients suffer from bone metastasis and weaknesses, which can be very painful,the entire Quantum Surgical’s team is delighted to obtain the new CE mark. New patients in Europe will be able to benefit from our innovative technology and will therefore experience a more comfortable health care pathway” says Bertin Nahum, CEO and co-founder of Quantum Surgical.

"The clinical study conducted at Gustave Roussy has demonstrated the relevance of Epione in the practice of bone percutaneous procedures. We will keep integrating robotics in these procedures which allow for better patient care" explains Dr. Baptiste Bonnet, interventional radiologist at Gustave Roussy.

Laetitia Messner, Chief Clinical Officer at Quantum Surgical develops “Conducted by Dr. Bonnet, the clinical study has demonstrated the clinical performance and safety of Epione in the treatment of bone lesions and, more broadly, in the execution of percutaneous bone procedures, which until now had been performed manually. The expanded careoffering provided by Epione will support both physicians and patients throughout the therapeutic pathway”.

Epione is currentlyavailable in about fifteen hospitals in Europe and in the United States.  

Epione® device is CE marked for abdomen, chest and musculoskeletal structures indications, and FDA cleared for abdominal ablation indication.

About Quantum Surgical

QuantumSurgical is a company specializing in medical robotics company and artificial intelligence co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team ofover 130 employees, the company has offices in Montpellier, France, and Miami,Florida.

Its Epione^® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. More than 1,000patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

Moreinformation: www.quantumsurgical.com

[1] Info Cancer

[2] Gustave Roussy, 2025

[3] Image-Guided Bone Consolidation in Oncology

‍